Plenary Session

Friday, September 29, 2023

2:15 PM – 4:15 PM EEST

Location: Trianti

Co-Chair(s)

Robert Orlowski, PhD, MD (he/him/his)

Florence Maude Thomas Cancer Research ProfessorDirector, Myeloma Section & Deputy Department ChairThe Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Qing Yi, MD, PhD (he/him/his)

Associate Director
Houston Methodist Neal Cancer Center
Houston, Texas, United States

Presentations:

2:15 PM – 2:25 PM EEST

OA-20: Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial.
Speaker: Alejandro Medina-Herrera, PhD – Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC
2:25 PM – 2:30 PM EEST

Summarize Abstract
Speaker: Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA
2:30 PM – 2:35 PM EEST

Audience Q&A
2:35 PM – 2:45 PM EEST

OA-27: Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma
Speaker: Parvathi Sudha, MS (she/her/hers) – Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
2:45 PM – 2:50 PM EEST

Summarize Abstract
Speaker: Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary
2:50 PM – 2:55 PM EEST

Audience Q&A
2:55 PM – 3:05 PM EEST

OA-45: Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial
Speaker: Carlos Fernandez de Larrea, MD, PhD – Hospital Clínic de Barcelona
3:05 PM – 3:10 PM EEST

Summarize Abstract
Speaker: Tom Martin, MD (he/him/his) – UCSF
3:10 PM – 3:15 PM EEST

Audience Q&A
3:15 PM – 3:25 PM EEST

OA-48: Isatuximab plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Final Overall Survival Analysis
Speaker: Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France
3:25 PM – 3:30 PM EEST

Summarize Abstract
Speaker: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
3:30 PM – 3:35 PM EEST

Audience Q&A
3:35 PM – 3:45 PM EEST

OA-52: Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Speaker: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca
3:45 PM – 3:50 PM EEST

Summarize Abstract
Speaker: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
3:50 PM – 3:55 PM EEST

Audience Q&A
3:55 PM – 4:05 PM EEST

OA-53: Peripheral Blood and Bone Marrow Residual Disease Negativity to Identify a Subgroup of Newly Diagnosed Multiple Myeloma Patients with Long Term Disease Control
Speaker: Noemi Puig, MD, PhD – Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IBSAL)
4:05 PM – 4:10 PM EEST

Summarize Abstract
Speaker: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
4:10 PM – 4:15 PM EEST

Audience Q&A